WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:



(I),

wherein

R^1 is -H, -C_{1-6} alkyl, -C_{3-6} cycloalkyl, or -C_{1-6} alkyl which is substituted with 1 or 2 substituents each of which is independently:

(1) C_{3-8} cycloalkyl,

(2) aryl,

(3) a 5- or 6-membered saturated or mono-unsaturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S,

(4) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or

(5) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic;

wherein

(A) each cycloalkyl is optionally substituted with from 1 to 3 substituents, each of which is independently halo, -C_{1-6} alkyl, or -O-C_{1-6} alkyl;

(B) each aryl is optionally substituted with from 1 to 5 substituents each of which is independently

(1) -C_{1-6} alkyl, optionally substituted with from 1 to 3 substituents each of which is independently -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -NO_2, -$N(R^aR^b)$, -$C(=O)N(R^aR^b)$, -$C(=O)R^a$, -CO_2R^c, -$S(O)_nR^c$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

BEST AVAILABLE COPY

(2) -O-C_{1-6} alkyl, optionally substituted with from 1 to 3 substituents each of which is independently -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -$S(O)_n R^c$, -$C(=O)N(R^aR^b)$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(3) -C_{1-6} haloalkyl,

(4) -O-C_{1-6} haloalkyl,

(5) -OH,

(6) halo,

(7) -CN,

(8) -NO_2,

(9) -$N(R^aR^b)$,

(10) -$C(=O)N(R^aR^b)$,

(11) -$C(=O)R^a$,

(12) -CO_2R^c,

(13) -SR^c,

(14) -$S(=O)R^c$,

(15) -SO_2R^c,

(16) -$N(R^a)SO_2R^c$,

(17) -$SO_2N(R^aR^b)$,

(18) -$N(R^a)C(=O)R^b$, or

(19) -$N(R^a)CO_2R^c$;

(C) each saturated or mono-unsaturated heterocyclic ring is

(i) optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and

(D) each heteroaromatic ring or each fused bicyclic heterocycle is

(i) optionally substituted with from 1 to 7 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or -C_{1-6} alkyl-aryl;

R^2 is -H or -C_{1-6} alkyl;

R^3 is -H, -C_{1-6} alkyl, -C_{1-6} haloalkyl, or -C_{1-6} alkyl substituted with one of -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -NO_2, -$N(R^aR^b)$, -$C(=O)N(R^aR^b)$, -$C(=O)R^a$, -CO_2R^c, -$S(O)_nR^c$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$;

R^4 is:

(1) -H,

(2) -C_{1-6} alkyl optionally substituted with one of -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -NO_2, -$N(R^aR^b)$, -$C(=O)N(R^aR^b)$, -$C(=O)R^a$, -CO_2R^c, -$S(O)_nR^c$, -$SO_2N(R^aR^b)$, -$N(R^a)$-$C(R^b)$=O, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, -$N(R^a)C(=O)N(R^aR^b)$, -O-C_{1-6} alkyl-$C(=O)N(R^aR^b)$, -S-C_{1-6} alkyl-$C(=O)N(R^aR^b)$, -$N(R^a)$-C_{1-6} alkyl-$C(=O)N(R^aR^b)$, or -$N(SO_2R^c)$-C_{1-6} alkyl-$C(=O)N(R^aR^b)$,

(3) -C_{1-6} haloalkyl,

(4) -$C(=O)R^a$,

(5) -CO_2R^c,

(6) -$C(=O)N(R^aR^b)$,

(7) -$SO_2N(R^aR^b)$,

(8) -C_{2-6} alkenyl,

(9) -C_{2-6} alkenyl-$C(=O)$-$N(R^a)_2$,

(10) -C_{2-5} alkynyl,

(11) -C_{2-5} alkynyl-$CH_2N(R^a)_2$,

(12) -C_{2-5} alkynyl-CH_2OR^a,

(13) -C_{2-5} alkynyl-$CH_2S(O)_nR^c$, or

(14) -R^k,

(15) -C_{1-6} alkyl substituted with R^k,

(16) -C_{1-6} haloalkyl substituted with R^k,
(17) -C_{1-6} alkyl-O-R^k,
(18) -C_{1-6} alkyl-O-C_{1-6} alkyl-R^k,
(19) -C_{1-6} alkyl-$S(O)_n$-R^k,
(20) -C_{1-6} alkyl-$S(O)_n$-C_{1-6} alkyl-R^k,
(21) -C_{1-6} alkyl-$N(R^a)$-R^k,
(22) -C_{1-6} alkyl-$N(R^a)$-C_{1-6} alkyl-R^k,
(23) -C_{1-6} alkyl-$N(R^a)$-C_{1-6} alkyl-OR^k, with the proviso that the -$N(R^a)$- moiety and the -OR^k moiety are not both attached to the same carbon of the -C_{1-6} alkyl- moiety,
(24) -C_{1-6} alkyl-C(=O)-R^k,
(25) -C_{1-6} alkyl-C(=O)$N(R^a)$-R^k,
(26) -C_{1-6} alkyl-$N(R^a)$C(=O)-R^k,
(27) -C_{1-6} alkyl-C(=O)$N(R^a)$-C_{1-6} alkyl-R^k, or
(28) -C_{1-6} alkyl-$N(R^a)$-C_{0-6} alkyl-$S(O)_nR^k$;

wherein R^k is

(i) aryl, which is optionally substituted with from 1 to 5 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} alkyl-OH, -C_{1-6} alkyl-O-C_{1-6} alkyl, -C_{1-6} alkyl-O-C_{1-6} haloalkyl, -C_{1-6} alkyl-$N(R^aR^b)$, -C_{1-6} alkyl-C(=O)$N(R^aR^b)$, -C_{1-6} alkyl-C(=O)R^a, -C_{1-6} alkyl-CO_2R^c, -C_{1-6} alkyl-$S(O)_nR^c$, -O-C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} haloalkyl, -OH, halo, -$N(R^aR^b)$, -C(=O)$N(R^aR^b)$, -C(=O)R^a, -CO_2R^c, -$S(O)_nR^c$, or -$SO_2N(R^aR^b)$;

(ii) a 4- to 7-membered saturated or mono-unsaturated heterocyclic ring containing at least one carbon atom and from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heterocyclic ring is:

(a) optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

(b) optionally mono-substituted with aryl or HetA;

wherein HetA is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally fused with a benzene ring, and HetA is optionally substituted with from 1 to 4

substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; or

(iii) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo;

R^5 is -H or -C_{1-6} alkyl;

R^6 is:

(1) -OH,
(2) -O-C_{1-6} alkyl,
(3) -N(R^uR^v),
(4) -O-C_{1-6} haloalkyl,
(5) -O-C_{1-6} alkyl-aryl
(6) -O-C_{1-6} alkyl-HetB, or
(7) -O-C_{1-6} alkyl-HetC,

wherein

R^u is -H or -C_{1-6} alkyl;

R^v independently has the same definition as R^1;

HetB is a 5- or 6-membered saturated or mono-unsaturated ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the ring is optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo;

each R^a and R^b is independently -H or -C_{1-6} alkyl;

each R^c is independently a -C_{1-6} alkyl; and

each n is independently an integer equal to 0, 1 or 2.

2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is -C_{1-4} alkyl mono-substituted with aryl; wherein the aryl is optionally substituted with from 1 to 4 substituents each of which is independently

(1) -C_{1-4} alkyl, optionally mono-substituted with -OH, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, -CN, -$N(R^aR^b)$, -$C(=O)N(R^aR^b)$, -$C(=O)R^a$, -CO_2R^c, -$S(O)_nR^c$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(2) -O-C_{1-4} alkyl, optionally mono-substituted with -OH, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, -$S(O)_nR^c$, -$N(R^a)$-CO_2R^c, -$C(=O)N(R^aR^b)$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(3) -C_{1-4} haloalkyl,

(4) -O-C_{1-4} haloalkyl,

(5) -OH,

(6) halo,

(7) -CN,

(8) -NO_2,

(9) -$N(R^aR^b)$,

(10) -SR^c,

(11) -$S(=O)R^c$,

(12) -SO_2R^c,

(13) -$N(R^a)SO_2R^c$,

(14) -$SO_2N(R^aR^b)$,

(15) -$N(R^a)C(=O)R^b$, or

(16) -$N(R^a)CO_2R^c$; and

R^6 is:

(1) -OH,

(2) -O-C_{1-6} alkyl,
(3) -N(R^uR^v),
(4) -O-C_{1-6} haloalkyl,
(5) -O-C_{1-6} alkyl-aryl
(6) -O-C_{1-6} alkyl-HetB, or
(7) -O-C_{1-6} alkyl-HetC,

wherein

R^u is -H or -C_{1-6} alkyl;

R^v is -H, -C_{1-6} alkyl, -C_{3-6} cycloalkyl, or independently has the same definition as R^1 above;

HetB is a 5- or 6-membered saturated or mono-unsaturated ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the ring is optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

HetC is a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein the heteroaromatic ring is optionally substituted with from 1 to 4 substituents each of which is independently -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo.

3. The compound according to claim 2, or a pharmaceutically acceptable salt thereof, wherein in R^1 is -$(CH_2)_{1-4}$-phenyl, wherein the phenyl is optionally substituted with from 1 to 3 substituents each of which is independently

(1) -C_{1-4} alkyl, optionally mono-substituted with -OH, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, -CN, -N(R^aR^b), -C(=O)N(R^aR^b), -C(=O)R^a, -CO_2R^c, -$S(O)_nR^c$, or -SO_2N(R^aR^b),
(2) -O-C_{1-4} alkyl,
(3) -C_{1-4} haloalkyl,
(4) -O-C_{1-4} haloalkyl,
(5) -OH,
(6) halo,
(7) -CN,
(8) -NO_2,

(9) -N(R^aR^b),
(10) -SR^c,
(11) -S(=O)R^c,
(12) -SO_2R^c,
(13) -N(R^a)SO_2R^c,
(14) -SO_2N(R^aR^b),
(15) -N(R^a)C(=O)R^b, or
(16) -N(R^a)CO_2R^c.

4. The compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein R^1 is:



;

wherein X^1 and X^2 are each independently
(1) -H,
(2) methyl,
(3) ethyl,
(4) methoxy,
(5) ethoxy,
(6) -CF_3,
(7) fluoro,
(8) bromo, or
(9) chloro.

5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein R^1 is 4-fluorobenzyl.

6. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^2 is -H or -C_{1-4} alkyl;

R^3 is -H or -C_{1-4} alkyl;

R^4 is:

(1) -H,
(2) -C_{1-4} alkyl optionally substituted with one of -OH, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, -CN, -$N(R^aR^b)$, -$C(=O)N(R^aR^b)$, -$C(=O)R^a$, -CO_2R^c, -$S(O)_nR^c$, -$SO_2N(R^aR^b)$, -$N(R^a)$-$C(R^b)=O$, -$N(R^a)SO_2R^b$, or -$N(R^a)SO_2N(R^aR^b)$,
(3) -$C(=O)N(R^aR^b)$,
(4) -R^k,
(5) -C_{1-4} alkyl substituted with R^k,
(6) -C_{1-4} alkyl-O-R^k, or
(7) -C_{1-4} alkyl-O-C_{1-4} alkyl-R^k; and

R^5 is -H.

7. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R^6 is:

(1) -OH,
(2) -O-C_{1-4} alkyl,
(3) -$N(R^uR^v)$,
(4) -O-C_{1-4} haloalkyl,
(5) -O-C_{1-4} alkyl-aryl
(6) -O-C_{1-4} alkyl-HetB, or
(7) -O-C_{1-4} alkyl-HetC,

wherein

R^u is -H or -C_{1-4} alkyl;

R^v is -H, -C_{1-4} alkyl, or cyclopropyl;

HetB is a 5- or 6-membered saturated ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the saturated ring is optionally substituted with from 1 to 4 substituents each of which is independently halogen, -C_{1-4} alkyl, -C_{1-4} haloalkyl, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, or oxo; and

HetC is a 5- or 6-membered heteroaromatic ring containing a total of from 1 to 4 heteroatoms independently selected from 1 to 4 N atoms, from 0 to 2 O atoms, and from 0 to 2 S atoms, wherein the heteroaromatic ring is optionally substituted with from 1 to 3 substituents each of which is independently -C_{1-4} alkyl, -C_{1-4} haloalkyl, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, or oxo.

8. A compound of Formula (II), or a pharmaceutically acceptable salt thereof:



(II),

wherein:

$X^{1'}$ and $X^{2'}$ are each independently:

(1) -H,
(2) C_{1-4} alkyl,
(2) -O-C_{1-4} alkyl,
(3) -C_{1-4} haloalkyl,
(4) -O-C_{1-4} haloalkyl, or
(5) halo; and

$R^{6'}$ is:

(1) -OH,
(2) -O-C_{1-4} alkyl, or
(3) -$N(R^uR^v)$;

wherein

R^u is -H or -C_{1-4} alkyl; and

R^v is -C_{1-4} alkyl or cyclopropyl.

9. A compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein:

wherein $X^{1'}$ and $X^{2'}$ are each independently:

(1) -H,
(2) methyl,
(2) $-OCH_3$,
(3) $-CF_3$,
(4) $-OCF_3$,
(5) chloro,
(6) fluoro, or
(7) bromo; and

$R^{6'}$ is:

(1) -OH,
(2) methoxy
(3) ethoxy
(4) $-N(R^uR^v)$;

wherein

R^u is -H; and

R^v is methyl, ethyl, or cyclopropyl.

10. The compound according to claim 8, which is a compound of Formula (III), or a pharmaceutically acceptable salt thereof:



(III),

wherein $X^{1'}$ and $X^{2'}$ are each independently -H or halo.

11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein

$X^{1'}$ and $X^{2'}$ are each independently -H, fluoro, chloro, or bromo; and

$R^{6'}$ is:

(1) -OH,
(2) methoxy
(3) ethoxy
(4) -N(R^uR^v);

wherein

R^u is -H; and

R^v is methyl, ethyl, or cyclopropyl.

12. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of Formula (IV):



(IV),

wherein

R^u is -H or -C_{1-6} alkyl;

R^v is C_{1-6} alkyl which is substituted with 1 or 2 substituents each of which is independently:

(1) C_{3-8} cycloalkyl,
(2) aryl,
(3) a 5- or 6-membered saturated or mono-unsaturated heterocyclic ring containing from 1 to 4 heteroatoms independently selected from N, O and S,
(4) a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S, or
(5) a 9- or 10-membered fused bicyclic heterocycle containing from 1 to 4 heteroatoms independently selected from N, O and S, wherein at least one of the rings is aromatic;

wherein

(A) each cycloalkyl is optionally substituted with from 1 to 3 substituents, each of which is independently halo, -C_{1-6} alkyl, or -O-C_{1-6} alkyl;

(B) each aryl is optionally substituted with from 1 to 5 substituents each of which is independently

(1) -C_{1-6} alkyl, optionally substituted with from 1 to 3 substituents each of which is independently -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -CN, -NO_2, -$N(R^aR^b)$, -$C(=O)N(R^aR^b)$, -$C(=O)R^a$, -CO_2R^c, -$S(O)_nR^c$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(2) -O-C_{1-6} alkyl, optionally substituted with from 1 to 3 substituents each of which is independently -OH, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, -$S(O)_nR^c$, -$C(=O)N(R^aR^b)$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(3) -C_{1-6} haloalkyl,

(4) -O-C_{1-6} haloalkyl,

(5) -OH,

(6) halo,

(7) -CN,

(8) -NO_2,

(9) -$N(R^aR^b)$,

(10) -$C(=O)N(R^aR^b)$,

(11) -$C(=O)R^a$,

(12) -CO_2R^c,

(13) -SR^c,

(14) -$S(=O)R^c$,

(15) -SO_2R^c,

(16) -$N(R^a)SO_2R^c$,

(17) -$SO_2N(R^aR^b)$,

(18) -$N(R^a)C(=O)R^b$, or

(19) -$N(R^a)CO_2R^c$;

(C) each saturated or mono-unsaturated heterocyclic ring is

(i) optionally substituted with from 1 to 5 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or a 5- or 6-membered heteroaromatic ring containing from 1 to 4 heteroatoms independently selected from N, O and S; and

(D) each heteroaromatic ring or each fused bicyclic heterocycle is

(i) optionally substituted with from 1 to 7 substituents each of which is independently halogen, -C_{1-6} alkyl, -C_{1-6} haloalkyl, -O-C_{1-6} alkyl, -O-C_{1-6} haloalkyl, or oxo; and

(ii) optionally substituted with 1 or 2 substituents each of which is independently aryl or -C_{1-6} alkyl-aryl; and

R^1 is -H or -C_{1-6} alkyl.

13. The compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein R^V is -C_{1-4} alkyl mono-substituted with aryl; wherein the aryl is optionally substituted with from 1 to 4 substituents each of which is independently

(1) -C_{1-4} alkyl, optionally mono-substituted with -OH, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, -CN, -$N(R^aR^b)$, -$C(=O)N(R^aR^b)$, -$C(=O)R^a$, -CO_2R^c, -$S(O)_nR^c$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(2) -O-C_{1-4} alkyl, optionally mono-substituted with -OH, -O-C_{1-4} alkyl, -O-C_{1-4} haloalkyl, -$S(O)_nR^c$, -$N(R^a)$-CO_2R^c, -$C(=O)N(R^aR^b)$, -$SO_2N(R^aR^b)$, -$N(R^a)C(=O)R^b$, -$N(R^a)CO_2R^c$, -$N(R^a)SO_2R^c$, -$N(R^a)SO_2N(R^aR^b)$, -$OC(=O)N(R^aR^b)$, or -$N(R^a)C(=O)N(R^aR^b)$,

(3) -C_{1-4} haloalkyl,

(4) -O-C_{1-4} haloalkyl,

(5) -OH,

(6) halo,

(7) -CN,

(8) -NO_2,

(9) -$N(R^aR^b)$,

(10) -SR^c,
(11) -$S(=O)R^c$,
(12) -SO_2R^c,
(13) -$N(R^a)SO_2R^c$,
(14) -$SO_2N(R^aR^b)$,
(15) -$N(R^a)C(=O)R^b$, or
(16) -$N(R^a)CO_2R^c$.

14. The compound according to claim 13, or a pharmaceutically acceptable salt thereof, wherein R^v is:



;

wherein X^1 and X^2 are each independently
(1) -H,
(2) methyl,
(3) ethyl,
(4) methoxy,
(5) ethoxy,
(6) -CF_3,
(7) fluoro,
(8) bromo, or
(9) chloro.

15. The compound according to claim 14, or a pharmaceutically acceptable salt thereof, wherein R^v is 4-fluorobenzyl.

16. The compound according to claim 12, or a pharmaceutically acceptable salt thereof, wherein:

R^u is -H;

R^5 is -H;

R^4 is:

(1) -H,
(2) -C_{1-4} alkyl optionally substituted with one of -OH, -$N(R^aR^b)$, or -$C(=O)N(R^aR^b)$,
(3) -$C(=O)N(R^aR^b)$,
(4) -$(CH_2)_{1-3}$-R^k,
(5) -$(CH_2)_{1-3}$-O-R^k, or
(6) -$(CH_2)_{1-3}$-O-$(CH_2)_{1-3}$-R^k;

R^2 is -H; and

R^1 is -C_{1-4} alkyl.

17. A compound selected from the group consisting of:



;



;



;


;


;


;


;


;


;


F
HN
N
H_3C
N
O
O
OH
;


OEt
N
F
N
O
O
OH
;


F
F
OEt
N
N
O
O
OH
;


Cl
OEt
N
N
O
O
OH
;


F
Cl
OEt
N
N
O
O
OH
;


Cl
Cl
OEt
N
N
O
O
OH
;



;



;



;

and pharmaceutically acceptable salts thereof.

18. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19. A method of inhibiting HIV integrase in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof.

20. A method for preventing or treating infection by HIV or for preventing, treating or delaying the onset of AIDS in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition which comprises the product prepared by combining an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

22. A combination useful for inhibiting HIV integrase, for treating or preventing infection by HIV, or for preventing, treating or delaying the onset of AIDS, which is a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an HIV infection/AIDS antiviral agent selected from the group consisting of HIV protease inhibitors, non-nucleoside HIV reverse transcriptase inhibitors and nucleoside HIV reverse transcriptase inhibitors.

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☑ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.